VRCI.L

Verici Dx plc
Verici Dx PLC - Notice of Results and Business Update
11th July 2024, 13:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0926W
Verici Dx PLC
11 July 2024
 

Verici Dx plc

("Verici Dx" or the "Company")

 

Notice of Results and Business Update

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it will report its interim results for the six months to 30 June 2024, together with a business update, on 15 July 2024.

 

Investor roadshow and briefings

 

Sara Barrington, Chief Executive Officer, and David Anderson, Chief Financial Officer, will provide a live online presentation via the Investor Meet Company platform on Tuesday 16th July 2024 at 16:30 BST. This presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00 am BST the day before the meeting or during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:

https://www.investormeetcompany.com/verici-dx-plc/register-investor

 

The Company will also be presenting in person at The Novotel, London on Wednesday 17 July 2024 at 18.00 BST as part of the regular series of "Shares" investor events hosted by AJ Bell. Existing shareholders and potential investors can register to attend this live evening event for free at: Shares Magazine - Events

 

Enquiries:

 

Verici Dx

www.vericidx.com

Sara Barrington, CEO

investors@vericidx.com

Julian Baines, Chairman

 



Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 20 7496 3000

Phil Davies / Sam Butcher


 

 

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORRBMBTMTABBII]]>
TwitterFacebookLinkedIn